Reportedly, Merck & Co., Inc. (MRK) has entered into multiple agreements to expand and support the manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines.
BARDA, the Biomedical Advanced Research and Development Authority, a unit of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services will also provide funding of up to $268.8 million to Merck to incorporate and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines.
“We are steadfast in our commitment to contribute to the global response to the pandemic as part of the remarkable efforts of the entire medical and scientific community. This funding from BARDA will allow us to accelerate our efforts to scale up our manufacturing capacity to enable timely delivery of much-needed medicines and vaccines for the pandemic.” stated Mike Nally, executive vice president, Human Health at Merck.
Merck has also entered into agreements with Janssen Pharmaceuticals, Inc. of Johnson & Johnson, to support the manufacturing and supply of Johnson & Johnson’s SARS-CoV-2/COVID-19 vaccine. Drug giant, Merck will use its facilities in the United States to help supply-constrained Johnson and Johnson manufacture its coronavirus vaccine.
As per the BARDA agreement, Merck will make available some of the company’s existing manufacturing sites to speed-up manufacturing efforts for COVID-19 vaccines and medicines.
The funding is in addition to Merck’s consistent investment in its global vaccines manufacturing network as part of its planned capital investments of more than $20 billion from 2020 to 2024 end.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
